TCGA-A8-A06N-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.380
- DNA_REPAIR+0.260
- HEME_METABOLISM+0.260
- PROTEIN_SECRETION+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.210
- OXIDATIVE_PHOSPHORYLATION+0.170
- BILE_ACID_METABOLISM+0.140
- PEROXISOME+0.110
- MYC_TARGETS_V1+0.090
- PANCREAS_BETA_CELLS+0.080
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.680
- ALLOGRAFT_REJECTION-0.560
- ANGIOGENESIS-0.530
- NOTCH_SIGNALING-0.480
- KRAS_SIGNALING_UP-0.450
- COAGULATION-0.430
- COMPLEMENT-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- INFLAMMATORY_RESPONSE-0.420
- APICAL_JUNCTION-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0ET-01A-31R-A034-07 | — | B | 0.885 |
| 2 | TCGA-AO-A0J3-01A-11R-A034-07 | — | B | 0.873 |
| 3 | AUR-AD9H-TTM2-A-1-1-R-A542-39 | — | B | 0.867 |
| 4 | MBCProject_0076_T1_RNA | — | B | 0.865 |
| 5 | R151 | — | — | 0.863 |
| 6 | SRR1797246 | — | cohortSC | 0.856 |
| 7 | fe4a0710-a6db-4735-9d1a-113df310def6 | — | — | 0.847 |
| 8 | TCGA-EW-A1OX-01A-11R-A144-07 | — | B | 0.840 |
| 9 | SRR1797242 | — | cohortSC | 0.839 |
| 10 | TCGA-E9-A5UO-01A-11R-A28M-07 | — | B | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |